{"id":109782,"date":"2026-06-18T10:41:04","date_gmt":"2026-06-18T10:41:04","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/alturos-therapeutics-advancement-of-lead-candidate-alt0135-a-potentially-first-in-class-orally-bioavailable-small-molecule-into-ind-enabling-studies\/"},"modified":"2026-06-18T10:41:04","modified_gmt":"2026-06-18T10:41:04","slug":"alturos-therapeutics-advancement-of-lead-candidate-alt0135-a-potentially-first-in-class-orally-bioavailable-small-molecule-into-ind-enabling-studies","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/alturos-therapeutics-advancement-of-lead-candidate-alt0135-a-potentially-first-in-class-orally-bioavailable-small-molecule-into-ind-enabling-studies\/","title":{"rendered":"Alturos Therapeutics advancement of lead candidate ALT0135, a potentially first-in-class, orally bioavailable small molecule, into IND-enabling studies"},"content":{"rendered":"
\n

www.alturostx.com<\/strong><\/p>\n

Tilburg, the Netherlands \u2013 June 18, 2026 <\/b>– Alturos Therapeutics B.V., <\/b>, a biopharmaceutical company focused on developing transformative therapies for neurodegenerative diseases, today announced the advancement of its lead candidate ALTO135, into IND-enabling studies, aiming to accelerate clinical development timelines. Alturos is developing small molecule therapies designed to target the earliest toxic triggers in Alzheimer\u2019s disease<\/a>, particularly protein oligomers that drive synaptic loss and neuronal death.<\/p>\n

Alturos\u2019 research is built on a pre-clinical drug discovery program previously acquired from Galapagos (now Lakefront\u00ae Biotherapeutics).<\/p>\n

ALT0135 is a derisked and potentially first-in-class, orally bioavailable small molecule with demonstrated central nervous system (CNS) penetration. This program aligns with Alturos\u2019 strategy to advance innovative neuroprotective approaches with a new mechanism of action supported by robust in vitro and in vivo efficacy data. By addressing upstream disease drivers and modulating downstream pathways associated with neuronal toxicity, the platform offers a differentiated approach to treating neurodegenerative disorders.<\/p>\n

\u201cWe are driven by the mission to provide patients with convenient oral and effective therapies fighting against neurodegenerative diseases<\/em>,\u201d said Jan Van der Schueren, PhD, co-founder and CEO of Alturos Therapeutics. \u201cI am excited to take this optimized small molecule, ALT0135, which has demonstrated clear benefits in preclinical in vivo models, into the clinic.\u201d<\/em><\/p>\n

=== E N D S ===<\/strong><\/p>\n

About Alturos Therapeutics<\/strong><\/p>\n

Alturos Therapeutics is a Dutch Belgian company, founded by a team of experienced industry veterans with proven track records in Alzheimer\u2019s and other neurodegenerative diseases. The company is currently involved in a Series A funding round, aiming to accelerate development and advance its lead candidate into IND-enabling studies on the path to clinical proof-of-concept.<\/p>\n

For more background info please visit our website www.alturostx.com<\/a>, or find us on Linkedin<\/a><\/p>\n

Please contact for more information:<\/b><\/p>\n

Alturos Therapeutics, Tilburg, the Netherlands<\/b><\/p>\n

E: <\/b>info@alturostx.com<\/a><\/p>\n

For media:<\/b><\/p>\n

LifeSpring LifeSciences Communication, Amsterdam, the Netherlands<\/b><\/p>\n

Leon Melens<\/p>\n

T:<\/b> +31 6 538 16427<\/p>\n

E:<\/b> lmelens@lifespring.nl<\/p>\n